IN THE SPECIFICATION

1. Delete the paragraph on page 18, lines 23-25, and replace it with:

Oil-emulsion compositions suitable for use as adjuvants in the invention include squalene-water emulsions, such as MF59® ~~MF59~~ (5% Squalene, 0.5% TWEEN® 80 ~~Tween 80~~, and 0.5% SPAN® 85 ~~Span 85~~, formulated into submicron particles using a microfluidizer). See ref. 45.

2. Delete the paragraph on page 21, lines 32-33, and replace it with:

Examples of imidazoquinolone compounds suitable for use adjuvants in the invention include Imiquimod ~~Imiquamod~~ and its homologues, described further in Ref. 80 and 81.

3. Delete the paragraphs on page 22, lines 6-12, and replace them with:

(5) SAF, containing 10% squalene ~~Squalane~~, 0.4% TWEEN® 80 ~~Tween 80~~, 5% pluronic-block polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion.

(6) RIBI™ ~~Ribi™~~ adjuvant system (RAS), (Ribi Immunochem) containing 2% Squalene, 0.2% TWEEN® 80 ~~Tween 80~~, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (DETOX™ ~~Detox™~~); and

4. Delete the paragraph on page 22, lines 15-16, and replace it with:

Aluminium salts and MF59® ~~MF59~~ are preferred adjuvants for parenteral immunisation. Mutant bacterial toxins are preferred mucosal adjuvants.

5. Delete the paragraph on page 23, line 5, and replace it with:

– rabies antigen(s) [*e.g.* 126] such as lyophilised inactivated virus [*e.g.* 127, RABAVERT™ ~~RabAvert™~~].